Connect Biopharma Holdings Limited, an inflammatory diseases treatment developer, has filed Amendment No 1 to Form F-1 Registration Statement on March 12, 2021 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. Assuming a successful IPO at the midpoint of the proposed price, the company expects a market capitalization of $863 million.
The company’s core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
The Taicang, China-based company was founded in 2012 and plans to list on the Nasdaq Global Market under the symbol “CNTB.” Jefferies, SVB Leerink, Piper Sandler and CICC are underwriters of the IPO.
The company engages Latham & Watkins LLP as US Securities Counsel, and PricewaterhouseCoopers Zhong Tian LLP as Independent Auditor.
#ipo #Nasdaq #ConnectBiopharma #inflammatory #diseases #treatment #Tcells
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
